CASCADE ONCOGENICS' CYCLIN E HISTOLOGY-BASED ANTIBODY BREAST CANCER DIAGNOSTIC TEST PMA SLATED FOR SUBMISSION "WITHIN SIX TO 12 MONTHS," CEO SAYS
This article was originally published in The Gray Sheet
Cascade Oncogenics plans to submit a premarket approval application for its Cyclin E breast cancer diagnostic test "within six to 12 months," Lynnor Stevenson, Cascade's president and CEO, said during an Aug. 12 session of the Medical Investments Northwest conference in Seattle.
You may also be interested in...
Arcadia prohibited from arguing against Advantice’s appeal of National Advertising Division decision that Kerasal Fungal Nail Renewal ad claims weren’t supported. Arcadia violated confidentiality rule by publicizing NAD decision before the review was officially closed.
The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.
Gallium has been approved as a diagnostic agent by the US agency to help early detection of prostate cancer spread in patients who qualify for treatment with surgery or radiation therapy.